Diamyd Medical gains market research findings to guide U.S. commercial strategy

Market research including initial interviews with US health care practioners as well as US payers demonstrated a strong willingness to consider prescribing the investigational precision medicine Diamyd[®] for Type 1 Diabetes and pricing in the range of USD 200,000. Diamyd[®] is currently being evaluated in the registrational Phase 3 trial DIAGNODE-3 in patients recently diagnosed with Type 1 Diabetes that carry the HLA DR3-DQ2 haplotype."These results both confirm and exceed our previous insights regarding pricing and the market potential of Diamyd in the US”, says Ulf Hannelius, CEO of